Target's General Information
Target ID T20761
Target Name Vascular endothelial growth factor A (VEGFA)
Synonyms Vascular permeability factor; VPF; VEGF-A; VEGF
Target Type Successful
Gene Name VEGFA
Biochemical Class Growth factor
UniProt ID VEGFA_HUMAN
Target's Expression Profile in Disease Related Tissue between Patients and Normal People
Disease Rectal cancer
Example drug Aflibercept Approved [1], [2], [3]
Tissue Rectal colon tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 1.2
Z-score: 2.26
P-value: 2.07E-03
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: 0.97
Z-score: 4.06
P-value: 1.28E-05
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Lateral sclerosis
Example drug SNN-0029 Phase 1/2 [2], [3], [4]
Tissue Cervical spinal cord
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.15
Z-score: 0.47
P-value: 3.61E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Target's Expression Profile across Various Tissues of Healthy Individual
References
REF 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
REF 2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF 3 NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.
REF 4 ClinicalTrials.gov (NCT01384162) An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.